Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Harel

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Cancer Research|October 15, 1988
Active specific immunotherapy for melanoma: phase I trial of allogeneic lysates and a novel adjuvantM S Mitchell, J Kan-Mitchell, R A Kempf, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1988
Effectiveness and tolerability of low-dose cyclophosphamide and low-dose intravenous interleukin-2 in disseminated melanoma [corrected]M S Mitchell, R A Kempf, W Harel, et al.
Cancer Research|October 1, 1990
Increased lysis of melanoma by in vivo-elicited human lymphokine-activated killer cells after addition of antiganglioside antibodies in vitroW Harel, H Shau, C G Hadley, et al.
Annals of the New York Academy of Sciences|August 12, 1993
Active specific immunotherapy of melanoma with allogeneic cell lysates. Rationale, results, and possible mechanisms of actionM S Mitchell, W Harel, J Kan-Mitchell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1990
Active-specific immunotherapy for melanomaM S Mitchell, W Harel, R A Kempf, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1991
Lymphocytes cytotoxic to uveal and skin melanoma cells from peripheral blood of ocular melanoma patientsJ Kan-Mitchell, P E Liggett, W Harel, et al.
Bulletin of the New York Academy of Medicine|January 1, 1989
Low-dose cyclophosphamide and low-dose interleukin-2 for malignant melanomaM S Mitchell, R A Kempf, W Harel, et al.
Cancer Immunology, Immunotherapy : CII|July 1, 1993
Clonal analysis of in vivo activated CD8+ cytotoxic T lymphocytes from a melanoma patient responsive to active specific immunotherapyJ Kan-Mitchell, X Q Huang, L Steinman, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Cancer Research|October 15, 1988
Active specific immunotherapy for melanoma: phase I trial of allogeneic lysates and a novel adjuvantM S Mitchell, J Kan-Mitchell, R A Kempf, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1988
Effectiveness and tolerability of low-dose cyclophosphamide and low-dose intravenous interleukin-2 in disseminated melanoma [corrected]M S Mitchell, R A Kempf, W Harel, et al.
Cancer Research|October 1, 1990
Increased lysis of melanoma by in vivo-elicited human lymphokine-activated killer cells after addition of antiganglioside antibodies in vitroW Harel, H Shau, C G Hadley, et al.
Annals of the New York Academy of Sciences|August 12, 1993
Active specific immunotherapy of melanoma with allogeneic cell lysates. Rationale, results, and possible mechanisms of actionM S Mitchell, W Harel, J Kan-Mitchell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1990
Active-specific immunotherapy for melanomaM S Mitchell, W Harel, R A Kempf, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1991
Lymphocytes cytotoxic to uveal and skin melanoma cells from peripheral blood of ocular melanoma patientsJ Kan-Mitchell, P E Liggett, W Harel, et al.
Bulletin of the New York Academy of Medicine|January 1, 1989
Low-dose cyclophosphamide and low-dose interleukin-2 for malignant melanomaM S Mitchell, R A Kempf, W Harel, et al.
Cancer Immunology, Immunotherapy : CII|July 1, 1993
Clonal analysis of in vivo activated CD8+ cytotoxic T lymphocytes from a melanoma patient responsive to active specific immunotherapyJ Kan-Mitchell, X Q Huang, L Steinman, et al.
Pageof 2